Cargando…

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study

Background: Cardiovascular (CV) diseases remain a leading and costly cause of death globally. Patients with previous CV events are at high risk of recurrence. Secondary prevention therapies improve CV risk factor control and reduce disease costs. Objectives: To assess the cost-effectiveness of a CV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aguiar, Carlos, Araujo, Francisco, Rubio-Mercade, Gabriel, Carcedo, David, Paz, Silvia, Castellano, Jose María, Fuster, Valentín
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2022
Materias:	Cardiovascular Conditions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687308/ https://www.ncbi.nlm.nih.gov/pubmed/36475278 http://dx.doi.org/10.36469/001c.39768

Ejemplares similares

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico
por: Gómez-Álvarez, Enrique, et al.
Publicado: (2020)

The Association of Economic Outcome and Geriatric Syndromes among Older Adults with Transcatheter Aortic Valve Replacement (TAVR)
por: Kwak, Min Ji, et al.
Publicado: (2020)

Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
por: Kodama, Kazuhisa, et al.
Publicado: (2020)

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
por: Peacock, W. Frank, et al.
Publicado: (2019)

Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism
por: Wang, Li, et al.
Publicado: (2019)

Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
por: Diel, Roland, et al.
Publicado: (2019)

A Systematic Literature Review of Three Stenting Strategies for Bifurcation Lesions in Coronary Artery Disease
por: Parsley-Raines, Larragem, et al.
Publicado: (2019)

Sternal-Wound Infections following Coronary Artery Bypass Graft: Could Implementing Value-Based Purchasing be Beneficial?
por: Brandt, Dominique, et al.
Publicado: (2020)

Real-world Bleeding Outcomes and Costs Following Vascular Graft Anastomosis Using PROLENE Sutures with HEMO-SEAL Technology in Patients Undergoing Abdominal Aortic Aneurysm Repair
por: Sutton, Nadia Y., et al.
Publicado: (2017)

The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation
por: Reynolds, Matthew R., et al.
Publicado: (2014)

An Algorithm to Analyze Cost Heterogeneity using Counterfactual Scenarios in Endovascular versus Open Repair of Abdominal Aortic Aneurysm: Predicting Costs for Subsequent Patients
por: Jones, Christopher A., et al.
Publicado: (2014)

The Cost Effectiveness of Hand Held Ultrasound Scanning for Abdominal Aortic Aneurysm in Older Males with a History of Smoking
por: Phiri, Denver, et al.
Publicado: (2013)

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain
por: Granero Xiberta, Xavier, et al.
Publicado: (2016)

Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
por: Berger, Ariel, et al.
Publicado: (2014)

The Cost of an Operating Room Minute for Heart Valve Procedures
por: Grossi, Eugene A., et al.
Publicado: (2015)

Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis
por: Han, Xue, et al.
Publicado: (2022)

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
por: Ruiz, George, et al.
Publicado: (2018)

The Association of COPD Exacerbations with New Onset Type 2 Diabetes among Medicare Patients
por: Marino, Joseph S., et al.
Publicado: (2017)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Cardiovascular Disease and Its Implication for Higher Catastrophic Health Expenditures Among Households in Sub-Saharan Africa
por: Adeniji, Folashayo Ikenna Peter, et al.
Publicado: (2023)

Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
por: Khaykin, Yaariv, et al.
Publicado: (2016)

One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States
por: Blanchette, Christopher M., et al.
Publicado: (2017)

New Oral Anaticoagulant Prescribing Decisions amongst General Practitioners: Handle with Care
por: Kirby, Ann, et al.
Publicado: (2017)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic Odyssey
por: Arnold, Renée JG, et al.
Publicado: (2015)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
por: Okumura, Ken, et al.
Publicado: (2015)

The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2023)

Correction: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2023)

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
por: van Gils, Paul F, et al.
Publicado: (2011)

Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke
por: Wald, Nicholas J., et al.
Publicado: (2016)

Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
por: Wood, Frances, et al.
Publicado: (2015)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2021)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Kandil, Omneya A., et al.
Publicado: (2022)

The polypill approach – An innovative strategy to improve cardiovascular health in Europe
por: Fuster, Valentín, et al.
Publicado: (2017)

Update on the CERN Computing and Network Infrastructure for Controls (CNIC)
por: Lüders, S
Publicado: (2007)

Update on the CERN Computing and Network Infrastructure for Controls (CNIC)
por: Lueders, S
Publicado: (2007)

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention
por: Roy, Ambuj, et al.
Publicado: (2017)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_c22ne6spjs2m3a772s31fr0llo